Furthermore, unlike EAI045 or brigatinib which showed limited antitumor effect without combined with anti-EGFR antibody 24, 26, HCD3514 as a single agent exhibited potent antitumor efficacy in tumor xenograft model in a dose-dependent manner without toxicity suggested the potential to target C797S mutant tumors. Here, EGFR is linked to neoplasm.